By Fineline Cube 
Hansoh Pharmaceutical Group (HKG: 3692) today announced a licensing agreement with Roche (SWX: ROG, OTCMKTS: RHHBY) that grants the Swiss biopharma company exclusive worldwide rights—outside Mainland China, Hong Kong, Macau, and Taiwan—to develop, commercialize, and market the antibody‑drug conjugate (ADC) HS‑20110. The deal is a milestone for Hansoh, positioning the CDH17‑targeting ADC on a path to global commercialization while securing a substantial upfront payment and future milestone and royalty upside.
Deal Highlights
| Item | Detail |
|---|---|
| Licensee | Roche |
| Product | HS‑20110 – CDH17‑targeting ADC with Topoisomerase I (TOPOi) payload |
| Geographic Scope | Exclusive rights worldwide, excluding Mainland China, Hong Kong, Macau, and Taiwan |
| Upfront Payment | $80 million |
| Milestone Structure | Payments tied to development, regulatory approval, and commercialization milestones |
| Royalty Structure | Tiered royalties on future product sales |
About HS‑20110
- Target – Cadherin‑17 (CDH17), overexpressed in a range of solid tumors, including colorectal cancer.
- Payload – Clinically validated Topoisomerase I inhibitor, designed to deliver potent cytotoxicity directly to CDH17‑positive tumor cells.
- Clinical Status – Early clinical trials have shown promising antitumor activity in solid tumor cohorts, with ongoing studies evaluating efficacy in colorectal cancer and other CDH17‑positive malignancies.
Strategic Significance
- For Hansoh Pharmaceutical – The $80 million upfront infusion strengthens R&D cash flow, while milestone and royalty upside aligns long‑term value with commercial success.
- For Roche – Acquisition of HS‑20110 expands Roche’s ADC portfolio into the CDH17 space, complementing its existing pipeline of antibody‑drug conjugates.
- For Patients – HS‑20110 may offer a novel therapeutic option for patients with CDH17‑positive solid tumors that are refractory to standard treatments.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech